Search results
Results from the WOW.Com Content Network
Apixaban is recommended by the National Institute for Health and Clinical Excellence for the prevention of stroke and systemic embolism in people with non-valvular atrial fibrillation and at least one of the following risk factors: prior stroke or transient ischemic attack, age 75 years or older, diabetes, or symptomatic heart failure.
Prior to the introduction of direct factor Xa inhibitors, vitamin K antagonists such as warfarin were the only oral anticoagulants for over 60 years, and together with heparin have been the main blood thinners in use. People admitted to hospital requiring blood thinning were started on an infusion of heparin infusion, which thinned blood ...
Andexanet alfa, sold under the brand name Andexxa among others, is an antidote for the medications rivaroxaban and apixaban, when reversal of anticoagulation is needed due to uncontrolled bleeding. [8] It has not been found to be useful for other factor Xa inhibitors. [9] It is given by injection into a vein. [9]
There are a few possible side effects linked to taking NSAIDs, including: gastrointestinal problems (such as irritation, ulcers, or bleeding), increased risk of heart attack and stroke, reduced ...
The study, which involved 106 peri- and postmenopausal women and was presented at the Endocrine Society’s annual meeting in May, indicates women should self-monitor their vasomotor symptoms and ...
While most patients take GLP-1 drugs with few or no serious side effects, it's common to experience at least mild gastrointestinal issues like nausea, vomiting, stomach pain, constipation, and ...
The p-methoxy group of apixaban connects to S1 pocket of FXa but does not appear to have any interaction with any residues in this region of FXa. The pyrazole N-2 nitrogen atom of apixaban interacts with Gln-192 and the carbonyl oxygen interacts with Gly-216. The phenyl lactam group of apixaban is positioned between Tyr-99 and Phe-174 and due ...
Cangrelor is the first reversible P2Y 12 inhibitor that can by administered intravenously and has a very fast onset and offset, which may provide advantages over current drugs and allow cangrelor to overcome these limitations of oral P2Y 12 inhibitor. This makes it an appealing option for antiplatelet therapy, especially for patients who are ...